COOKIES: By using this website you agree that we can place Google Analytics Cookies on your device for performance monitoring. |
University of Cambridge > Talks.cam > MRC Biostatistics Unit Seminars > Virtual BSU Seminar: "A flexible sensitivity analysis for sample selection bias"
Virtual BSU Seminar: "A flexible sensitivity analysis for sample selection bias"Add to your list(s) Download to your calendar using vCal
If you have a question about this talk, please contact Alison Quenault. This will be a virtual seminar. To register for free, please click here: https://www.eventbrite.co.uk/e/bsu-seminar-dr-matt-tudball-tickets-251838374357 Selection bias can occur when a sample differs systematically from the population from which it was drawn. This can distort statistical quantities and lead to erroneous inferences. Selection bias can be difficult to address when there is limited information available on the population. In this talk, I will describe a sensitivity analysis for selection bias which is able to flexibly incorporate a wide variety of population-level information (e.g. summary statistics, negative controls, shape constraints), while providing valid statistical inference. Applications include 1) estimating the effect of education on income in UK Biobank and 2) estimating risk factors for Covid-19 infection within a sample of individuals who have received a Covid-19 test. Please see the pre-print for more details: https://arxiv.org/abs/1906.10159 This talk is part of the MRC Biostatistics Unit Seminars series. This talk is included in these lists:
Note that ex-directory lists are not shown. |
Other listscued CISA Talks - Cambridge International Studies Association Conspiracy & DemocracyOther talksSmall-scale turbulence idealized by noise: some of its consequences The Thesan Project - simulating the high redshift Universe Improving Quality of Experience for Video Users in Cellular Networks Enduring Structures, Patterns of Change: ‘English’ Landscapes in the Northern Atlantic, 1000-1800CE The AKT inhibitor Capivasertib (AZD5363): from discovery to clinical proof of concept |